Conversely, inhibiting IL-6 signaling with the anti-IL-6 receptor monoclonal antibody tocilizumab, reduces peripheral blood plasmablasts and AQP4-IgG levels in some patients and appears to decrease relapse rates in NMO patients (Araki et al., 2014). This evidence concerns the gene IL6 and neuromyelitis optica.